losartan has been researched along with digoxin in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 14 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Avdeef, A; Tam, KY | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| De Meyer, G; De Smet, M; Fitzpatrick, V; Goldberg, MR; Schoors, DF; Somers, G; Verbesselt, R | 1 |
| Doris, PA; Kähönen, M; Kalliovalkama, J; Pekki, A; Pörsti, I; Tolvanen, JP; Voipio, J; Wu, X; Ylitalo, P | 1 |
| Baskurt, M; Kaya, A; Kucukoglu, S; Okcun, B; Ortak, K; Yigit, Z; Yildiz, A | 1 |
| Kamiyama, E; Mikkaichi, T; Nakai, D; Okazaki, O; Okudaira, N | 1 |
| Benndorf, RA; Böger, RH; Divac, N; Haefeli, WE; Herzog, M; Sauer, A; Schwedhelm, E; Weiss, J | 1 |
| Gorski, JC; Lindamood, C; Ortiz, S; Rackley, R; Shaw, A | 1 |
| Chong, E; Kalia, V; Willsie, S; Winkle, P | 1 |
| Doogue, MP; Miners, JO; Polasek, TM; Rowland, A; Snyder, BD | 1 |
| Boman, K; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K | 1 |
1 review(s) available for losartan and digoxin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 trial(s) available for losartan and digoxin
| Article | Year |
|---|---|
Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Biphenyl Compounds; Cardiotonic Agents; Cross-Over Studies; Digoxin; Double-Blind Method; Humans; Imidazoles; Injections, Intravenous; Losartan; Male; Tetrazoles | 1995 |
Comparison of rate and rhythm control in hypertension patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Calcium Channel Blockers; Cardiotonic Agents; Digoxin; Electric Countershock; Female; Follow-Up Studies; Humans; Hypertension; Losartan; Male; Metoprolol; Middle Aged; Survival Analysis; Treatment Outcome; Verapamil | 2008 |
Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Area Under Curve; Cardiotonic Agents; Chelating Agents; Digoxin; Diuretics; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; Ferric Compounds; Furosemide; Half-Life; Healthy Volunteers; Humans; Losartan; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Models, Statistical; Omeprazole; Proton Pump Inhibitors; Risk Assessment; Sucrose; Warfarin; Young Adult | 2014 |
Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.
Topics: Adult; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Calcium Channel Blockers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Felodipine; Female; Genotype; Humans; Losartan; Male; Midazolam; Omeprazole; Young Adult | 2014 |
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Digoxin; Electrocardiography; Female; Heart Failure; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Lipoproteins, HDL; Losartan; Male; Middle Aged; Risk | 2015 |
14 other study(ies) available for losartan and digoxin
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Arterial responses in vitro and plasma digoxin immunoreactivity after losartan and enalapril treatments in experimental hypertension.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Cardiomegaly; Digoxin; Dihydropyridines; Enalapril; Heart; Hypertension; Losartan; Male; Mesenteric Arteries; Muscle, Smooth, Vascular; Nifedipine; Organ Size; Potassium Chloride; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Sodium-Potassium-Exchanging ATPase; Tunica Media | 2000 |
Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes.
Topics: Adenosine Triphosphatases; Angiotensin II Type 1 Receptor Blockers; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Benzoates; Biological Transport; Biphenyl Compounds; Caco-2 Cells; Calcium Channel Blockers; Cardiotonic Agents; Cell Membrane; Digoxin; Drug Interactions; Humans; Irbesartan; Losartan; Telmisartan; Tetrazoles; Verapamil | 2010 |
Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Benzimidazoles; Biological Transport; Biphenyl Compounds; Digoxin; Fluoresceins; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Membrane Transport Proteins; Mice; Multidrug Resistance-Associated Protein 2; Olmesartan Medoxomil; Tetrazoles; Thiophenes | 2010 |
Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies.
Topics: Adult; Antihypertensive Agents; Benzopyrans; Cytochrome P-450 CYP2D6; Digoxin; Drug Interactions; Ethanolamines; Female; Fluoxetine; Furosemide; Genotype; Humans; Hydrochlorothiazide; Losartan; Male; Middle Aged; Nebivolol; Ramipril; Warfarin; Young Adult | 2011 |